NoticiasCon ayuda de IA

Johnson & Johnson Offers Historic $505M Deal To Talc Miners Amid Bankruptcy Fallout

J&J to pay $505M to settle disputes with talc suppliers amid ongoing cancer lawsuits.

Mrudula Kulkarni
Por Mrudula Kulkarni
Editor Gerente - Pharma Now
17 jul 2024Updated Jun 26, 2025 · 2 min de lectura
Johnson & Johnson Offers Historic $505M Deal To Talc Miners Amid Bankruptcy Fallout
https://www.foxbusiness.com/markets/jury-backs-johnson-johnson-in-talc-cancer-case
Reportaje con ayuda de IA
Reviewed by Mrudula Kulkarni, Editor Gerente - Pharma Now

As Johnson & Johnson faces ongoing lawsuits alleging that its talcum powder products cause cancer, the company is allocating substantial funds to resolve a long-running conflict with its suppliers. The proposed settlement involves Johnson & Johnson paying a minimum of $505 million to the bankrupt talc suppliers, Imerys Talc America and Cyprus Mines Corporation, by December 31, 2025. According to recent bankruptcy court documents, a portion of J&J's payments will be directed to the suppliers' settlement trust for talc claimants.

According to the proposed deal, Johnson & Johnson will first pay $225 million upfront, followed by an additional $280 million sourced from their insurance policies. This agreement follows the bankruptcies of Imerys in 2019 and Cyprus in 2021, as both companies sought protection from talc-related liabilities. Although other companies produce talc, Imerys has traditionally been the exclusive supplier of talc for Johnson & Johnson's cosmetic products. Legal filings indicate that lawsuits against Johnson & Johnson frequently include Imerys as a co-defendant.

The disputes between Imerys, Cyprus, and Johnson & Johnson revolve around indemnification agreements, which the talc suppliers argue should shield them from cancer-related liabilities. However, Imerys' 2019 bankruptcy filing reveals that Johnson & Johnson either denied the existence of these agreements or challenged their terms. In the midst of Johnson & Johnson's ongoing legal battles over its talc-based products, the company has reached a settlement with talc miners. As part of its recent bankruptcy plan for its talc litigation subsidiary, Johnson & Johnson has proposed almost $6.5 billion in settlement funds for ovarian cancer plaintiffs. Plaintiffs are currently considering this offer and are expected to vote on it by July 26.

 

TemasNews
Mrudula Kulkarni
Written by
Mrudula Kulkarni
Editor Gerente - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.



Discussion

Cargando la conversación…

Más de Pharma News

Todos los artículos →